Patent search ap:("Array BioPharma Page Inc.") AND inv:"Ginelle A. Ramann"

1.

发明申请
SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS 审中-公开

公开(公告)号：US20180133207A1

公开(公告)日：2018-05-17

申请号：US15860894

申请日：2018-01-03

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377

CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

2.

发明授权
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 有权

公开(公告)号：US10881652B2

公开(公告)日：2021-01-05

申请号：US16579150

申请日：2019-09-23

Applicant: Array Biopharma Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: C07D471/04 , A61K31/4545 , A61K31/4162 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

3.

发明申请
SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS 审中-公开

公开(公告)号：US20180148445A1

公开(公告)日：2018-05-31

申请号：US15858929

申请日：2017-12-29

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: C07D471/04 , A61P35/00 , A61P1/00

CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

4.

发明授权
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors 有权

公开(公告)号：US11472802B2

公开(公告)日：2022-10-18

申请号：US16962305

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： Shane M. Walls , Li Ren , Ginelle A. Ramann , David A. Moreno , Andrew T. Metcalf , Elizabeth A. McFaddin , Gabrielle R. Kolakowski , James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Dean Kahn

IPC: C07D471/04 , A61P35/00 , C07F9/6561

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

5.

发明授权
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 有权

公开(公告)号：US10144734B2

公开(公告)日：2018-12-04

申请号：US15858929

申请日：2017-12-29

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: C07D471/04 , A61K31/4162 , A61P1/00 , A61P35/00

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

6.

发明授权
Fused heterocyclic compounds as RET kinase inhibitors 有权

公开(公告)号：US11964988B2

公开(公告)日：2024-04-23

申请号：US17274990

申请日：2019-09-06

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Dean Kahn , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren , Shane M. Walls , Hailong Zhang

IPC: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22

CPC classification number: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

7.

发明授权
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 有权

公开(公告)号：US11648243B2

公开(公告)日：2023-05-16

申请号：US17108528

申请日：2020-12-01

Applicant: Array Biopharma Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. Mcfaddin , Megan L. Mckenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12

CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04

Abstract: Provided herein are compounds of the Formula I:

or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

8.

发明授权
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors 有权

公开(公告)号：US11603374B2

公开(公告)日：2023-03-14

申请号：US16962345

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.